Tags

Type your tag names separated by a space and hit enter

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
Vaccine 2007; 26(1):119-27V

Abstract

In a randomized, observer-blind, three-arm, parallel group, multi-centre trial including 386 elderly subjects in four countries, the immunogenicity and safety was studied of three different trivalent inactivated surface antigen (subunit) influenza vaccine types: a conventional subunit influenza vaccine (SIV, brand: Influvac and two newer vaccines: a MF59-adjuvanted subunit influenza vaccine (adSIV, brand: Fluad and a virosomal subunit influenza vaccine (vSIV, brand: Invivac. All vaccines were trivalent containing 15 microg hemagglutinin of each virus strain as recommended by the World Health Organization for the 2004-2005 season. The study was designed to demonstrate the serological non-inferiority of vSIV to both adSIV and SIV in elderly persons. The secondary objective was to investigate whether vSIV is superior to adSIV with respect to local reactogenicity. For all three vaccine strains, the post-vaccination geometric mean titres were comparable between SIV and adSIV and between vSIV and SIV. Seroprotection rates (i.e. percentages of subjects with a post-vaccination titre >or=40) varied between 84.1-100% indicating that the three vaccines all induced a strong antibody response. Local and systemic reactions were more frequently associated with adSIV (46 and 32%, respectively) than with vSIV or SIV (approximately 20%). Vaccinations caused only little inconvenience as measured by questionnaire. In general, all vaccines were safe and well tolerated. In this trial, virosomal vaccine had similar immunogenicity to MF59-adjuvanted and conventional subunit vaccine and was considerably less reactogenic than the MF59-adjuvanted vaccine in the elderly.

Authors+Show Affiliations

Clinical Development Influenza Vaccines, Solvay Pharmaceuticals, PO Box 900, NL-1380 DA Weesp, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

18063446

Citation

de Bruijn, Iris, et al. "Antibody Induction By Virosomal, MF59-adjuvanted, or Conventional Influenza Vaccines in the Elderly." Vaccine, vol. 26, no. 1, 2007, pp. 119-27.
de Bruijn I, Meyer I, Gerez L, et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine. 2007;26(1):119-27.
de Bruijn, I., Meyer, I., Gerez, L., Nauta, J., Giezeman, K., & Palache, B. (2007). Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine, 26(1), pp. 119-27.
de Bruijn I, et al. Antibody Induction By Virosomal, MF59-adjuvanted, or Conventional Influenza Vaccines in the Elderly. Vaccine. 2007 Dec 21;26(1):119-27. PubMed PMID: 18063446.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. AU - de Bruijn,Iris, AU - Meyer,Ingo, AU - Gerez,Lisya, AU - Nauta,Jos, AU - Giezeman,Katinka, AU - Palache,Bram, Y1 - 2007/11/12/ PY - 2007/07/03/received PY - 2007/10/09/revised PY - 2007/10/18/accepted PY - 2007/12/8/pubmed PY - 2008/2/22/medline PY - 2007/12/8/entrez SP - 119 EP - 27 JF - Vaccine JO - Vaccine VL - 26 IS - 1 N2 - In a randomized, observer-blind, three-arm, parallel group, multi-centre trial including 386 elderly subjects in four countries, the immunogenicity and safety was studied of three different trivalent inactivated surface antigen (subunit) influenza vaccine types: a conventional subunit influenza vaccine (SIV, brand: Influvac and two newer vaccines: a MF59-adjuvanted subunit influenza vaccine (adSIV, brand: Fluad and a virosomal subunit influenza vaccine (vSIV, brand: Invivac. All vaccines were trivalent containing 15 microg hemagglutinin of each virus strain as recommended by the World Health Organization for the 2004-2005 season. The study was designed to demonstrate the serological non-inferiority of vSIV to both adSIV and SIV in elderly persons. The secondary objective was to investigate whether vSIV is superior to adSIV with respect to local reactogenicity. For all three vaccine strains, the post-vaccination geometric mean titres were comparable between SIV and adSIV and between vSIV and SIV. Seroprotection rates (i.e. percentages of subjects with a post-vaccination titre >or=40) varied between 84.1-100% indicating that the three vaccines all induced a strong antibody response. Local and systemic reactions were more frequently associated with adSIV (46 and 32%, respectively) than with vSIV or SIV (approximately 20%). Vaccinations caused only little inconvenience as measured by questionnaire. In general, all vaccines were safe and well tolerated. In this trial, virosomal vaccine had similar immunogenicity to MF59-adjuvanted and conventional subunit vaccine and was considerably less reactogenic than the MF59-adjuvanted vaccine in the elderly. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/18063446/Antibody_induction_by_virosomal_MF59_adjuvanted_or_conventional_influenza_vaccines_in_the_elderly_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(07)01224-8 DB - PRIME DP - Unbound Medicine ER -